MD-ENVIVA
Today, the European Parliament once again voted to recognize primary woody biomass as a renewable energy source. This is consistent with its prior classification under both the first Renewable Energy Directive (RED) and RED II. Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, welcomes the designation as it marks a critical step in the right direction toward more low-carbon, drop-in alternatives to fossil fuels for power and heat generation, as part of an all-in renewables strategy to reduce carbon emissions and limit global dependence on fossil fuels.
Primary woody biomass is an essential renewable energy source for meeting the ambition sought by the EU Parliament to increase renewable energy to 45 percent by 2030, and for achieving the EU’s goal of carbon neutrality by 2050. In the words of Markus Pieper, the Member of Parliament leading on RED III, at the press conference held following the results of the plenary, “We do need wood-based biomass as a source of energy if we genuinely are to undertake this energy transition.”
The Parliament’s vote this week brings its position considerably closer to those of the Council and EU Commission by recognizing primary woody biomass as renewable, ensuring its continued zero-carbon rating in the EU Emissions Trading Scheme, and allowing its use to increase in volume.
“One thing is clear: wood-based biomass is a building block of the energy transition and, despite the vote of left-green Members of the European Parliament, can still be counted as renewable energy. The new directive will set the necessary framework to achieve the greatest possible CO2 reduction effect and not to ensure that our forests are burned in the future. I am counting on the member states to follow our proposals as the procedure progresses (“trilogue”),” continued Mr. Pieper in his statement.
The Council and EU Commission have continued their steadfast support for primary woody biomass and for its increased utilization to deliver climate change benefits and security of energy supply. Today’s vote serves as an initial negotiating position in the European Union’s process. After this vote, the EU Parliament, the Council of the EU, and the EU Commission will begin trilogue discussions, which are negotiations among the three parties, that are estimated to reach a final compromise on RED III in the first half of 2023.
“Heading into trilogues, the EU Parliament brought its position one step closer towards the mainstream views of the Council and the Commission, and away from the earlier minority position taken by the ENVI committee.
“While the process is foreign to those of us in the U.S., as an Austrian native, I can appreciate the complex nature of the EU legislative process, and that a compromise needs to be reached in trilogue negotiations to address the energy transition, security, and affordability crisis facing the EU. Today, biomass accounts for almost 60 percent of renewable energy in Europe.
“All serious pathways for achieving climate neutrality show that the use of bioenergy must and can be increased sustainably. The EU Commission’s own impact assessment for RED III outlines a need to increase bioenergy use from 2030 to 2050 by an average of 69 percent to provide vital grid balancing services, high temperature heat for industry, advanced biofuels, and negative emissions,” said Thomas Meth, President of Enviva.
“A failure to increase woody biomass use in the EU would mean failure in meeting climate goals, increased cost to EU consumers, and further disruption to security of energy supply on the brink of winter, when bioenergy makes up 25 percent of European heating supply and when incremental investments in more woody biomass infrastructure are desperately needed. At Enviva, we are encouraged by the progress made and are confident that a pragmatic and reasonable outcome will be reached,” concluded Meth.
About Enviva
Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.
To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
